61 related articles for article (PubMed ID: 35241735)
21. Drug resistance mechanisms in cancers: Execution of pro-survival strategies.
Dhanyamraju PK
J Biomed Res; 2024 Feb; 38(2):95-121. PubMed ID: 38413011
[TBL] [Abstract][Full Text] [Related]
22. miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma.
Park SE; Kim W; Hong JY; Kang D; Park S; Suh J; You D; Park YY; Suh N; Hwang JJ; Kim CS
Sci Rep; 2022 Mar; 12(1):3537. PubMed ID: 35241735
[TBL] [Abstract][Full Text] [Related]
23. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
[TBL] [Abstract][Full Text] [Related]
24. Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals.
Zhai W; Li S; Zhang J; Chen Y; Ma J; Kong W; Gong D; Zheng J; Xue W; Xu Y
Mol Cancer; 2018 Nov; 17(1):157. PubMed ID: 30419914
[TBL] [Abstract][Full Text] [Related]
25. Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A.
Xiao W; Lou N; Ruan H; Bao L; Xiong Z; Yuan C; Tong J; Xu G; Zhou Y; Qu Y; Hu W; Gao Y; Ru Z; Liu L; Xiao H; Chen K; Yang H; Zhang X
Cell Physiol Biochem; 2017; 43(6):2420-2433. PubMed ID: 29073615
[TBL] [Abstract][Full Text] [Related]
26. Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling.
Wang M; Sun Y; Xu J; Lu J; Wang K; Yang DR; Yang G; Li G; Chang C
Int J Cancer; 2018 Jul; 143(1):100-112. PubMed ID: 29396852
[TBL] [Abstract][Full Text] [Related]
27. Feedback activation of GATA1/miR-885-5p/PLIN3 pathway decreases sunitinib sensitivity in clear cell renal cell carcinoma.
Yao D; Xia S; Jin C; Zhao W; Lan W; Liu Z; Xiu Y
Cell Cycle; 2020 Sep; 19(17):2195-2206. PubMed ID: 32783497
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology of Renal Cell Carcinoma.
Padala SA; Barsouk A; Thandra KC; Saginala K; Mohammed A; Vakiti A; Rawla P; Barsouk A
World J Oncol; 2020 Jun; 11(3):79-87. PubMed ID: 32494314
[TBL] [Abstract][Full Text] [Related]
29. PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma.
Sekino Y; Hagura T; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shigeta M; Taniyama D; Kuraoka K; Sentani K; Yasui W; Matsubara A
Anticancer Res; 2020 Apr; 40(4):1943-1951. PubMed ID: 32234883
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-96 is a potential tumor repressor by inhibiting NPTX2 in renal cell carcinoma.
Xiang W; Han L; Mo G; Lin L; Yu X; Chen S; Gao T; Huang C
J Cell Biochem; 2020 Feb; 121(2):1504-1513. PubMed ID: 31498486
[TBL] [Abstract][Full Text] [Related]
31. miR-96-5p promotes the proliferation and migration of ovarian cancer cells by suppressing Caveolae1.
Liu B; Zhang J; Yang D
J Ovarian Res; 2019 Jun; 12(1):57. PubMed ID: 31228941
[TBL] [Abstract][Full Text] [Related]
32. LncRNA STXBP5-AS1 suppressed cervical cancer progression via targeting miR-96-5p/PTEN axis.
Shao S; Wang C; Wang S; Zhang H; Zhang Y
Biomed Pharmacother; 2019 Sep; 117():109082. PubMed ID: 31212131
[TBL] [Abstract][Full Text] [Related]
33. miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells.
Vahabi M; Pulito C; Sacconi A; Donzelli S; D'Andrea M; Manciocco V; Pellini R; Paci P; Sanguineti G; Strigari L; Spriano G; Muti P; Pandolfi PP; Strano S; Safarian S; Ganci F; Blandino G
J Exp Clin Cancer Res; 2019 Mar; 38(1):141. PubMed ID: 30925916
[TBL] [Abstract][Full Text] [Related]
34. The miR-183/182/96 cluster functions as a potential carcinogenic factor and prognostic factor in kidney renal clear cell carcinoma.
Yuan J; Dong R; Liu F; Zhan L; Liu Y; Wei J; Wang N
Exp Ther Med; 2019 Apr; 17(4):2457-2464. PubMed ID: 30906433
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
